Giant cell tumors of the bone: Changes in image features after denosumab administration

Sota Oguro, Shigeo Okuda, Hiroaki Sugiura, Shunsuke Matsumoto, Aya Sasaki, Michiro Susa, Hideo Morioka, Masahiro Jinzaki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To assess the clinical importance in the feature change in giant cell tumors of the bone (GCTB) after denosumab treatment, detected by MRI. Methods: In 12 patients, MRI and CT of GCTB obtained before and after the treatment retrospectively compared. The tumor size, the signal intensity (SI) ratio between the solid part of the GCTB and muscle, cystic part size, gadolinium enhancement and apparent diffusion coefficient (ADC) value were measured on MRI. The bone formation in the tumor was observed on CT and X-ray. Results: The mean number of denosumab injections was 19 ± 10. The follow-up period was up to 2 years. One case showed partial remission, while the other 11 cases were stable. A mean SI ratio on T2-weighted image statistically significantly decreased from 3.9 to 1.9 after the treatment. A cystic component in the tumor was observed in five cases before the treatment, and the diameter of the cystic part decreased after the treatment in 80% of cases (4/5). All the tumors showed contrast enhancement on T1-weighted image pre-and post-treatment (11/11). The averaged ADC values were 1.52 × 10−3 mm2/s before and 1.44 × 10−3 mm2/s after the treatment (P = 0.63). Bone formation in the tumor was observed in 58% of cases (7/12). Conclusion: The decrease of SI ratio on T2-weighted image, shrinkage of cystic part and bone formation should be regarded as the effectiveness of denosumab treatment despite of no substantial change in the tumor size.

Original languageEnglish
Pages (from-to)325-330
Number of pages6
JournalMagnetic Resonance in Medical Sciences
Volume17
Issue number4
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Giant Cell Tumor of Bone
Osteogenesis
Neoplasms
Therapeutics
X Ray Computed Tomography
Gadolinium
Denosumab
Muscles
Injections

Keywords

  • Denosumab
  • Giant cell tumor of bone
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Giant cell tumors of the bone : Changes in image features after denosumab administration. / Oguro, Sota; Okuda, Shigeo; Sugiura, Hiroaki; Matsumoto, Shunsuke; Sasaki, Aya; Susa, Michiro; Morioka, Hideo; Jinzaki, Masahiro.

In: Magnetic Resonance in Medical Sciences, Vol. 17, No. 4, 01.01.2018, p. 325-330.

Research output: Contribution to journalArticle

Oguro, Sota ; Okuda, Shigeo ; Sugiura, Hiroaki ; Matsumoto, Shunsuke ; Sasaki, Aya ; Susa, Michiro ; Morioka, Hideo ; Jinzaki, Masahiro. / Giant cell tumors of the bone : Changes in image features after denosumab administration. In: Magnetic Resonance in Medical Sciences. 2018 ; Vol. 17, No. 4. pp. 325-330.
@article{17258356203e4f5d9dff70c3245ba5ae,
title = "Giant cell tumors of the bone: Changes in image features after denosumab administration",
abstract = "Purpose: To assess the clinical importance in the feature change in giant cell tumors of the bone (GCTB) after denosumab treatment, detected by MRI. Methods: In 12 patients, MRI and CT of GCTB obtained before and after the treatment retrospectively compared. The tumor size, the signal intensity (SI) ratio between the solid part of the GCTB and muscle, cystic part size, gadolinium enhancement and apparent diffusion coefficient (ADC) value were measured on MRI. The bone formation in the tumor was observed on CT and X-ray. Results: The mean number of denosumab injections was 19 ± 10. The follow-up period was up to 2 years. One case showed partial remission, while the other 11 cases were stable. A mean SI ratio on T2-weighted image statistically significantly decreased from 3.9 to 1.9 after the treatment. A cystic component in the tumor was observed in five cases before the treatment, and the diameter of the cystic part decreased after the treatment in 80{\%} of cases (4/5). All the tumors showed contrast enhancement on T1-weighted image pre-and post-treatment (11/11). The averaged ADC values were 1.52 × 10−3 mm2/s before and 1.44 × 10−3 mm2/s after the treatment (P = 0.63). Bone formation in the tumor was observed in 58{\%} of cases (7/12). Conclusion: The decrease of SI ratio on T2-weighted image, shrinkage of cystic part and bone formation should be regarded as the effectiveness of denosumab treatment despite of no substantial change in the tumor size.",
keywords = "Denosumab, Giant cell tumor of bone, Magnetic resonance imaging",
author = "Sota Oguro and Shigeo Okuda and Hiroaki Sugiura and Shunsuke Matsumoto and Aya Sasaki and Michiro Susa and Hideo Morioka and Masahiro Jinzaki",
year = "2018",
month = "1",
day = "1",
doi = "10.2463/mrms.mp.2017-0072",
language = "English",
volume = "17",
pages = "325--330",
journal = "Magnetic Resonance in Medical Sciences",
issn = "1347-3182",
publisher = "Japan Society of Magnetic Resonance in Medicine",
number = "4",

}

TY - JOUR

T1 - Giant cell tumors of the bone

T2 - Changes in image features after denosumab administration

AU - Oguro, Sota

AU - Okuda, Shigeo

AU - Sugiura, Hiroaki

AU - Matsumoto, Shunsuke

AU - Sasaki, Aya

AU - Susa, Michiro

AU - Morioka, Hideo

AU - Jinzaki, Masahiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To assess the clinical importance in the feature change in giant cell tumors of the bone (GCTB) after denosumab treatment, detected by MRI. Methods: In 12 patients, MRI and CT of GCTB obtained before and after the treatment retrospectively compared. The tumor size, the signal intensity (SI) ratio between the solid part of the GCTB and muscle, cystic part size, gadolinium enhancement and apparent diffusion coefficient (ADC) value were measured on MRI. The bone formation in the tumor was observed on CT and X-ray. Results: The mean number of denosumab injections was 19 ± 10. The follow-up period was up to 2 years. One case showed partial remission, while the other 11 cases were stable. A mean SI ratio on T2-weighted image statistically significantly decreased from 3.9 to 1.9 after the treatment. A cystic component in the tumor was observed in five cases before the treatment, and the diameter of the cystic part decreased after the treatment in 80% of cases (4/5). All the tumors showed contrast enhancement on T1-weighted image pre-and post-treatment (11/11). The averaged ADC values were 1.52 × 10−3 mm2/s before and 1.44 × 10−3 mm2/s after the treatment (P = 0.63). Bone formation in the tumor was observed in 58% of cases (7/12). Conclusion: The decrease of SI ratio on T2-weighted image, shrinkage of cystic part and bone formation should be regarded as the effectiveness of denosumab treatment despite of no substantial change in the tumor size.

AB - Purpose: To assess the clinical importance in the feature change in giant cell tumors of the bone (GCTB) after denosumab treatment, detected by MRI. Methods: In 12 patients, MRI and CT of GCTB obtained before and after the treatment retrospectively compared. The tumor size, the signal intensity (SI) ratio between the solid part of the GCTB and muscle, cystic part size, gadolinium enhancement and apparent diffusion coefficient (ADC) value were measured on MRI. The bone formation in the tumor was observed on CT and X-ray. Results: The mean number of denosumab injections was 19 ± 10. The follow-up period was up to 2 years. One case showed partial remission, while the other 11 cases were stable. A mean SI ratio on T2-weighted image statistically significantly decreased from 3.9 to 1.9 after the treatment. A cystic component in the tumor was observed in five cases before the treatment, and the diameter of the cystic part decreased after the treatment in 80% of cases (4/5). All the tumors showed contrast enhancement on T1-weighted image pre-and post-treatment (11/11). The averaged ADC values were 1.52 × 10−3 mm2/s before and 1.44 × 10−3 mm2/s after the treatment (P = 0.63). Bone formation in the tumor was observed in 58% of cases (7/12). Conclusion: The decrease of SI ratio on T2-weighted image, shrinkage of cystic part and bone formation should be regarded as the effectiveness of denosumab treatment despite of no substantial change in the tumor size.

KW - Denosumab

KW - Giant cell tumor of bone

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=85053123641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053123641&partnerID=8YFLogxK

U2 - 10.2463/mrms.mp.2017-0072

DO - 10.2463/mrms.mp.2017-0072

M3 - Article

C2 - 29386457

AN - SCOPUS:85053123641

VL - 17

SP - 325

EP - 330

JO - Magnetic Resonance in Medical Sciences

JF - Magnetic Resonance in Medical Sciences

SN - 1347-3182

IS - 4

ER -